Q&A: Till­man Gern­gross ex­plains why his Covid mAb will have an edge over an al­ready crowd­ed field

If any­one knows about mon­o­clon­al an­ti­bod­ies, it’s se­r­i­al en­tre­pre­neur, Adimab CEO, and Dart­mouth pro­fes­sor of bio­engi­neer­ing Till­man Gern­gross.

Even the name of Gern­gross’ new an­ti­body start­up Ada­gio Ther­a­peu­tics is meant to re­flect his vi­sion be­hind the de­vel­op­ment of his Covid-19 mAb: slow­ly, he said, ex­plain­ing that “every­one else, whether it’s Re­gen­eron, Lil­ly, or As­traZeneca, Vir, they all val­ued speed over every­thing.”

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN